Antiepidermal growth factor receptor monoclonal antibody improves survival outcomes in the treatment of patients with metastatic colorectal cancer

Anti-Cancer Drugs

Volumn 23, Issue 2, 2012, Pages 155-160

  Wang, Lida ^a   Chen, Xuemei ^b   Li, Wei ^b   Sheng, Zhixin ^a  

^a WEIFANG MEDICAL UNIVERSITY   (China)

^b Binzhou Center Hospital   (China)

Author keywords

anti epidermal growth factor receptor monoclonal body; colorectal cancer; overall survival

Indexed keywords

CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN; PANITUMUMAB;

CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; COCHRANE LIBRARY; COLORECTAL CANCER; DRUG EFFICACY; EMBASE; HAZARD RATIO; HUMAN; LONG TERM CARE; MEDLINE; METASTASIS; ONCOGENE K RAS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCISEARCH; WILD TYPE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; HUMANS; MUTATION; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84855213337     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32834c3256     Document Type: Review

References (20)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108. (Pubitemid 40372904)
2. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000; 343:905-914.
3. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23-30. (Pubitemid 41095110)
4. Van Cutsem E, Geboes K. The multidisciplinary management of gastrointestinal cancer. The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer. Best Pract Res Clin Gastroenterol 2007; 21:1089-1108.
5. Kang X, Patel D, Ng S, Melchior M, Ludwig D, Hicklin D. High affinity Fc receptor binding and potent induction of antibody-dependent cellular cytotoxicity (ADCC) in vitro by anti-epidermal growth factor receptor antibody cetuximab. J Clin Oncol 2007; 25 (suppl):128s; abstract 3041.
6. Hamilton SR. Targeted therapy of cancer: New roles for pathologists in colorectal cancer. Mod Pathol 2008; 21 (suppl 2):S23-S30. (Pubitemid 351592774)
7. Van Cutsem E, Köhne CH, Lá ng I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29:2011-2019.
8. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27:663-671.
9. Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT,Wilson RH, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: Results of the randomised phase 3 MRC COIN trial. Lancet 2011; 377:2103-2114.
10. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359:1757-1765.
11. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007; 8:16.
12. Siena S, Cassidy J, Tabernero J, Burkes RL, Barugel ME, Humblet Y, et al. Randomized phase 3 study of panitumumab with FOLFOX4 Versus FOLFOX4 alone as first-line treatment in patients with metastatic colorectal cancer: The PRIME trial. Eur J Cancer 2009; 7 (suppl):6.
13. Nie F, Shen J, Tong JL, Xu XT, Zhu MM, Ran ZH. Meta-analysis: The efficacy and safety of monoclonal antibody targeted to epidermal growth factor receptor in the treatment of patients with metastatic colorectal cancer. J Dig Dis 2009; 10:247-257.
14. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998; 17:2815-2834. (Pubitemid 28562978)
15. Borner M, Koeberle D, Von Moos R, Saletti P, Rauch D, Hess V, et al. Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: A randomized phase II trial of the Swiss group for clinical cancer research SAKK. Ann Oncol 2008; 19:1288-1292. (Pubitemid 351911959)
16. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapyrefractory metastatic colorectal cancer. J Clin Oncol 2007; 25: 1658-1664. (Pubitemid 46797944)
17. Amado RG,Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:1626-1634.
18. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357:2040-2048. (Pubitemid 350106711)
19. Sobrero AF, Maurel J, Fehrenbacher L, ScheithauerW, Abubakr YA, Lutz MP, et al. EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:2311-2319.
20. Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28:4706-4713 [Epub 2010 Oct 4].